U.S. Water Utilities Stock News

What Ionis’ latest update means for shareholders Ionis Pharmaceuticals (IONS) kicked off 2026 by spotlighting 2025 milestones, including US$105 million in preliminary TRYNGOLZA net sales and progress across several late stage RNA therapies with key regulatory and clinical updates ahead. For you as a shareholder or potential investor, this kind of multi program update matters because it links current commercial performance with a set of upcoming decision points that could influence Ionis'...

Gold Resource Corporation reported a past fourth‑quarter 2025 operational turnaround at its Don David Gold Mine, with higher‑grade ore from the Three Sisters area driving record silver sales and a shift toward silver‑weighted production. This operational improvement marks a meaningful change in the company’s revenue mix, increasing its exposure to silver‑linked performance at the Don David operation. We’ll now look at how this operational turnaround and Three Sisters’ higher‑grade ore shape...

Why Structure Therapeutics (GPCR) Is Back on Investors’ Radar Structure Therapeutics (GPCR) is drawing fresh attention after recent analyst commentary pointed to growing confidence in its obesity pipeline, including key trial progress for aleniglipron and a new licensing deal with Genentech. The agreement with Genentech includes a US$100 million upfront payment and potential royalties, while analysts are watching upcoming clinical milestones such as the 44 week ACCESS II readout and a planned...

LKQ Corporation recently reported a Q3 2025 earnings beat and raised its 2025 adjusted EPS guidance to a range of US$3 to US$3.15, even as analysts now expect a year-on-year earnings decline for Q4 2025. This combination of stronger-than-expected recent performance and higher full-year guidance, set against forecasts for softer Q4 results, has sharpened investor focus on the company’s earnings quality and outlook. We’ll now look at how LKQ’s raised 2025 adjusted EPS guidance shapes its...

If you are wondering whether Power Integrations is attractively priced or still has work to do before looking compelling, its recent price moves and valuation checks give you some useful clues. The share price last closed at US$42.90, with returns of 4.9% over the past week and 17.3% over the past month. The year to date return is 15.0% and the 1-year return is a 30.9% decline. Recent coverage has focused on how Power Integrations fits into the wider semiconductor space and how investors are...

If you are wondering whether Array Digital Infrastructure is still fairly priced after its recent run, this article walks through what the current share price could imply about the company's value. The stock last closed at US$56.55, with returns of 5.4% over 7 days, 9.0% over 30 days, 4.7% year to date and 28.5% over 1 year, plus a very large 3 year gain and a 136.8% return over 5 years. Recent news coverage has focused on Array Digital Infrastructure's position in digital infrastructure and...

Event context and recent return profile Saia (SAIA) has moved quietly on the back of recent trading rather than a single headline event. This puts the focus on how its share performance lines up with the underlying business. Over the past month the stock shows a 6.4% gain, while the past 3 months and 1 year reflect moves of about 10.2% and a 32.6% decline, respectively. This sets a mixed backdrop for investors to evaluate. See our latest analysis for Saia. The recent 1 day and 7 day share...

If you are wondering whether Fresh Del Monte Produce at around US$37.30 still offers value, it helps to look past the headline price and focus on what the market is actually paying for its cash flows and assets. The stock has returned 2.0% over the last 7 days, 5.6% year to date and 21.9% over the past year, with a 51.8% return over 3 years and 72.5% over 5 years. This gives useful context before weighing up what that current price might imply. Recent coverage has focused on Fresh Del Monte...

Hancock Whitney (NasdaqGS:HWC) has completed a bond portfolio restructuring aimed at supporting net interest margin and earnings. Management is pursuing organic growth by hiring additional revenue focused bankers and has authorized a new share buyback program. Devon Bray has been appointed director of Business Banking, with a focus on client relationships and digital capabilities. Hancock Whitney, a regional bank with a focus on commercial and retail clients along the Gulf South, is...

What Carlisle Companies stock performance tells you now Carlisle Companies (CSL) has been relatively steady, with the share price up around 6% over the past month and about 5% over the past 3 months, despite a 1 day decline. For longer term holders, the picture is mixed, with a 6% gain year to date but an estimated 13% total return decline over the past year, set against very large 3 year and 5 year total return multiples. See our latest analysis for Carlisle Companies. At a share price of...

Dave (NasdaqGM:DAVE) has appointed Nima Khajehnouri, Meta’s VP of Engineering, to its Board of Directors. The move brings additional AI and data engineering expertise to the company during an ongoing board reshuffle. The appointment is part of Dave’s push to deepen its technical leadership in the neobanking space. For you as an investor, this board change comes at a time when Dave’s stock has seen sharp moves. Shares recently closed at $185.27, with a 1 year return of 103.8% and a 3 year...

Earlier this week, Reliance Industries reported Q3 results that grew revenue but missed market expectations, as retail EBITDA growth slowed and margins eased while the oil and gas segment saw declines in revenue and EBITDA. Despite solid contributions from Jio Platforms and the oil-to-chemicals business, investor attention has focused on how competitive pressures and higher costs are reshaping the profitability profile of Reliance’s retail operations. Next, we’ll explore how the earnings...

Fresh attention has turned to DRDGOLD (DRD) after a recent Peter Lynch style GARP screen flagged the stock for its combination of profit growth, low debt levels, and a clear focus on gold waste retreatment. See our latest analysis for DRDGOLD. At a share price of $37.66, DRDGOLD has seen strong recent momentum, with a 20.55% 1 month share price return and a 49.44% 3 month share price return contributing to a very large 1 year total shareholder return. This suggests that investors may be...

If you are trying to work out whether NextDecade's current share price still reflects its long term potential, the key question is how the stock stacks up against its underlying value. The share price closed at US$4.86 recently, after a 7.4% decline over the last week and a 11.3% decline over the last month, with the one year return at a 46.3% loss and the five year return at 78.7%. Recent news around NextDecade has focused on its role in US liquefied natural gas projects and its efforts to...

If you are wondering whether SLM's share price still reflects good value after its long run as a student lending name, you are not alone. The stock last closed at US$26.00, with returns of a 3.1% decline over 7 days, a 4.9% decline over 30 days, a 5.1% decline year to date, and a 7.4% decline over 1 year. The 3 year and 5 year returns sit at 65.1% and 120.9% respectively. Recent coverage has focused on how SLM fits into the broader student loan and consumer credit conversation, with...

Recent share performance snapshot With no fresh company specific headlines driving Harley-Davidson (HOG) today, the focus for investors is on the stock’s recent performance and fundamentals, including returns, revenue, earnings and its diversified business segments. See our latest analysis for Harley-Davidson. At a share price of US$20.10, Harley-Davidson’s recent 1 day, 7 day and 30 day share price returns show steady declines, and the 1 year and 5 year total shareholder returns indicate...

Edgewise Therapeutics (EWTX) updated investors on its late stage pipeline, outlining 2026 milestones for muscular dystrophy and cardiovascular programs. These include key sevasemten trial readouts and a potential future New Drug Application submission. See our latest analysis for Edgewise Therapeutics. The update on 2026 clinical milestones comes as Edgewise Therapeutics trades at $28.73, with a 90 day share price return of 92.95% and a 3 year total shareholder return of 160.24%. This...

If you are wondering whether VeriSign's share price still reflects fair value or if expectations have run ahead of the fundamentals, you are in the right place. VeriSign shares most recently closed at US$248.12, with returns of 0.7% over the last 7 days, 1.7% over the last 30 days, 3.2% year to date and 18.9% over 1 year, while the 3 and 5 year returns sit at 16.1% and 27.7% respectively. These price moves sit against a backdrop of ongoing attention on domain infrastructure providers and the...

If you are wondering whether Paycom Software's current share price lines up with its underlying value, you are not alone. This article is built to help you size that up clearly. The stock closed at US$147.48, with returns of a 6.4% decline over 7 days, a 9.4% decline over 30 days, a 3.2% decline year to date and a 29.0% decline over 1 year, alongside a 53.0% decline over 3 years and a 61.6% decline over 5 years, which may have shifted how investors view its risk and potential reward. Recent...

We wouldn't blame Delta Air Lines, Inc. ( NYSE:DAL ) shareholders if they were a little worried about the fact that...

Why Edwards Lifesciences (EW) Is On Investors’ Radar Today Edwards Lifesciences (EW) is drawing attention after a period where the stock showed a mix of modest short term declines and a stronger 1 year total return. This performance is prompting some market participants to reassess its recent results and characteristics. See our latest analysis for Edwards Lifesciences. At a share price of US$83.46, Edwards Lifesciences has seen its short term share price momentum cool, with a 1 day decline...

If you are looking at Qorvo and wondering whether the current share price reflects fair value or an opportunity, you are not alone. The stock last closed at US$79.85, with returns of a 0.5% decline over 7 days, a 6.8% decline over 30 days, a 7.4% decline year to date and an 8.8% decline over 1 year, alongside longer term returns of a 26.1% decline over 3 years and a 54.4% decline over 5 years. Recent attention on Qorvo has centered on how these share price moves fit with its position in the...

Option Care Health (OPCH) has drawn fresh attention after expanding its share repurchase authorization to US$1b, completing earlier buybacks, and issuing full year 2026 net revenue guidance of US$5.8b to US$6.0b. See our latest analysis for Option Care Health. Those announcements come after a strong run in the share price, with a 30 day share price return of 10.09% and a 90 day share price return of 26.51%, while the 1 year total shareholder return of 21.45% and 5 year total shareholder...

Earlier this month, National Vision Holdings, Inc. reaffirmed its earnings guidance for the 53 weeks ended January 3, 2026, maintaining expected net revenue between US$1.97 billions and US$1.99 billions. This confirmation of the revenue outlook reinforces management’s confidence in the company’s operating trajectory and offers investors increased clarity on near-term expectations. Next, we’ll examine how National Vision’s decision to reaffirm full-year earnings guidance shapes the company’s...